LivaNova PLC (LIVN) — ESG & Values Scores

Environment story

LivaNova demonstrates baseline environmental management with ISO 14001 and ISO 45001 certifications at key manufacturing facilities (Mirandola, Italy; Munich, Germany). The company discloses minimal direct environmental controversies in provided filings. However, critical gaps exist: Scope 1, Scope 2, and Scope 3 emissions are entirely undisclosed; no net-zero target date or climate commitment is disclosed; no verified investments in decarbonization infrastructure are documented. The company operates manufacturing in multiple jurisdictions and purchases components globally, creating potential supply-chain emissions exposure that remains unquantified. Environmental compliance risks are acknowledged (Saluggia Site hazardous substances, SNIA environmental litigation) but detailed remediation timelines and financial provisions are not fully transparent in this excerpt. Without quantified emissions baselines and credible reduction targets, environmental score reflects only operational certifications without substantive climate performance.

Criticisms on file

Saluggia Site Hazardous Substances Liability
Source: LIVN 10-K Note 11 Commitments and Contingencies; disclosed as unresolved environmental liability from prior operations
SNIA Environmental Litigation
Source: LIVN 10-K Note 11 Commitments and Contingencies; ongoing litigation related to environmental contamination
No Disclosed Scope 1, 2, or 3 Emissions & No Net-Zero Target
Source: LIVN 10-K 2025 filing; comprehensive review of MD&A, Risk Factors, and business description shows zero quantified GHG data or climate commitments

Disclosed initiatives

ISO 14001 Certification (Mirandola & Munich facilities)

Environmental management system certification at Mirandola, Italy and Munich, Germany manufacturing plants

Structured environmental compliance framework; no quantified emissions reduction or renewable-energy transition disclosed
ISO 45001 Certification (Occupational Health & Safety)

Occupational health and safety management system at key manufacturing sites

Worker safety infrastructure; indirect environmental benefit through hazard control

Social story

LivaNova reports ~3,300 employees across 80+ nationalities in 34 countries as of December 31, 2025. The company articulates diversity and inclusion commitments (Multi-Generation Network, Women in Sales, Women's Network mentorship programs) and conducts annual employee engagement surveys (LivaNova4You with 94% participation in early 2026). Performance management, training (LivaNova University), and professional development programs are documented. However, critical quantitative diversity metrics—workforce gender/racial composition, leadership diversity percentages, CEO-to-median-worker pay ratio—are entirely absent from provided filings. No formal supply-chain human-rights audits, conflict-minerals policies, or modern-slavery statements are disclosed. Union standing is unclear; the company acknowledges collective-bargaining agreements and works-council consultation requirements in multiple jurisdictions but provides no detail on labor relations, strikes, or NLRB complaints. Compensation and benefits programs are outlined qualitatively (bonuses, equity, health coverage, parental leave, education reimbursement) but lack wage-equity commitments or pay-gap disclosures. Turnover rate is not disclosed.

Criticisms on file

Complete Absence of Quantified Diversity Metrics
Source: LIVN 10-K 2025 filing; MD&A and Human Capital Management section disclose no workforce gender %, racial composition %, or leadership diversity %
No CEO-to-Median-Worker Pay Ratio Disclosure
Source: LIVN 10-K 2025 filing; executive compensation and human capital sections lack pay-ratio transparency
No Supply-Chain Human-Rights or Conflict-Minerals Policy Disclosed
Source: LIVN 10-K 2025 filing; production and supply-chain sections acknowledge worldwide suppliers and manufacturing but no ethical audits, modern-slavery statements, or human-rights due diligence documented
Undisclosed Turnover Rate & Union Status Detail
Source: LIVN 10-K 2025 filing; collective-bargaining and works-council obligations acknowledged but no labor-relations metrics, strikes, or formal union partnerships documented

Disclosed initiatives

Diversity Affinity Programs

Multi-Generation Network, Women in Sales, LivaNova Women's Network with mentorship programs (U.S. and Latin America); employee engagement focusing on diversity perspectives and inclusion

Internal support structures; no quantified leadership advancement or retention metrics
LivaNova4You Employee Engagement Survey

Annual survey covering health/wellness, engagement, transformation, and culture; 94% participation in early 2026 with identified strengths (purpose, strategy clarity, inclusion, collaboration) and gaps (career development, workload management, leadership well-being role-modeling)

Data-driven feedback mechanism; action plan implementation not detailed
LivaNova University & Professional Development

Extensive internal training library; external education reimbursement programs; leadership development; internships and apprenticeships globally

Skill-building and internal mobility support; effectiveness not quantified
Compensation & Benefits Programs

Base pay, annual bonuses, share awards, pensions, health/well-being, paid leave, parental leave, financial education assistance, flexible/hybrid/remote work, employee share plans, employee rewards

Competitive total-rewards structure; no pay-equity or wage-gap disclosure

Governance story

LivaNova's governance structure and board composition are not explicitly detailed in provided filings. The company is a public limited company organized under English law, listed on Nasdaq under ticker LIVN. The 10-K references Board of Directors charters and Corporate Governance Guidelines available on the company website but does not disclose board independence percentage, board size, dual-class share structure, or director tenure in the excerpt provided. The company is subject to FDA, EU MDR, HIPAA, GDPR, FCPA, UK Bribery Act, and comprehensive healthcare/anti-corruption regulations. Lobbying expenditures are not quantified in provided materials. The company discloses Iran operations (~$10.9M revenue FY2025, ~$5.8M profit) representing <1% of consolidated revenue, compliant with sanctions law per company assertion. Environmental litigation (Saluggia, SNIA) and potential regulatory compliance costs are flagged but not quantified. No antitrust proceedings, FDA warning letters, or significant compliance fines are disclosed in excerpt. The company emphasizes FCPA and anti-corruption compliance programs but provides no metrics on enforcement, audits, or violations.

Criticisms on file

November 2023 Cybersecurity Incident with Unresolved Impact
Source: LIVN 10-K 2025 Risk Factors section 'Failure to protect, maintain, or upgrade LivaNova's IT systems'; incident resulted in disruption to portions of IT systems; remediation status, financial impact, and governance response not quantified
Iran Operations Disclosure (~$10.9M FY2025 Revenue)
Source: LIVN 10-K Item 13(r) Section 13(r) of Exchange Act 1934; non-U.S. subsidiaries sell medical devices to distributors and NGOs in Iran; company asserts compliance with sanctions but acknowledges limited visibility into end-customers and potential government-entity involvement
Saluggia Site Environmental Liability & SNIA Litigation
Source: LIVN 10-K Note 11 Commitments and Contingencies; unresolved environmental contingencies from prior operations; financial provisions and resolution timeline not detailed
Undisclosed Board Independence %, Dual-Class Structure, & Lobbying Spend
Source: LIVN 10-K 2025 filing; governance details referenced as available on website but not quantified in SEC filing excerpt; no lobbying expenditure disclosure

Disclosed initiatives

ISO 13485 Quality System Certification

Quality management system certified for design, development, manufacturing, warehousing, and distribution to ensure product safety and effectiveness

Regulatory compliance infrastructure; no governance-specific outcome metrics
FCPA & Anti-Corruption Compliance Program

Company subject to FCPA, UK Bribery Act, and international anti-corruption laws; compliance monitoring and employee/consultant agreements in place

Risk mitigation framework; no audit results or violation disclosures provided
Data Privacy & Cybersecurity Governance

HIPAA, GDPR, CCPA compliance programs; Data Protection Officer appointed; Data Protection Impact Assessments conducted; multi-jurisdictional privacy program

Structured data governance; cybersecurity incident of November 2023 disclosed but remediation status and financial impact not detailed
Corporate Governance Guidelines & Board Charters

Board charters and Corporate Governance Guidelines maintained; website disclosure of governance framework

Governance transparency mechanism; detailed board composition, independence %, and voting structure not disclosed in excerpt

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of LivaNova PLC. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open LivaNova PLC in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)